🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

1/ JUST IN: an 8 year #kidneycancer journey now published in nature: “A personalized neoantigen vaccine generates anti-tumor immunity in high-risk renal cell carcinoma”. A trial of #RCC vaccine, led together with first author David Braun Yale Cancer Center and #PatrickOtt #DerinKeskin

Ab#96 ASCO #GU25 by Christopher Wallis (he/him/his)👉bit.ly/3EqF5TB👉In pts w/ de novo mHSPC #prostatecancer (n = 6051) 👉Only 24% received intensified ADT & sociodemographic marginalization was associated w/ ⬇️rates of intensified Rx👇Aly-Khan Lalani OncoAlert UroToday.com PCF Science

We'll be filming live at 2025 ASCO Genitourinary Cancer Symposium, which starts tomorrow! Aly-Khan Lalani and Christopher Wallis (he/him/his) will weigh-in with their reactions, considerations, and key learnings from the sessions and presentations in an exciting 3-episode series. Stay tuned! #GU25

#GU25: Longer term follow up for front-line #RCC combinations — many studies now with ~5+ years! 🚨 👏 Bar is set for next disruptors (MOAs?) to displace Toni Choueiri, MD Tom Powles Brian Rini, MD Robert Motzer MD Laurence Albiges Rana McKay, MD, FASCO Sumanta K. Pal, MD, FASCO Neeraj Agarwal, MD, FASCO Yüksel Ürün OncoAlert ASCO

Filmed live at ASCO GU, in Episode 17 of The View on GU, Dr @LalaniMD & Dr Christopher Wallis (he/him/his) consider “the age-old question” when it comes to prostate cancer: radiation or surgery? To listen, visit theviewongu.ca. Part 2 & Part 3 of this ASCO mini-series is coming soon! #GU25

🚨Episode 18 is out! The second episode in our mini-series from ASCO GU focuses on #BladderCancer. Dr. Aly-Khan Lalani & Dr. Christopher Wallis (he/him/his) talk about CheckMate 247, a Phase 3 clinical trial using adjuvant nivolumab in resected urothelial cancer. Check it out at theviewongu.ca!

Join us for this event in #RCC.Navigating the Evolving Landscape of Renal Cell Carcinoma: From Case Studies to Comprehensive Care. Sign up for free: cuaregistration.org/navigating-the… #kidney #section1credits Aly-Khan Lalani Ramy Saleh, MD, MSc

Episode 20 of The View on GU is officially live! 🥳🎉 Special guest Dr. Katherine Zukotynski joins Dr. @LalaniMD and Dr. Christopher Wallis (he/him/his) to discuss radioligand therapy. Watch or listen to Episode 20 now! theviewongu.ca.

Theranostics is changing the game in #ProstateCancer care. In Ep. 20 of The View on GU, Dr. Katherine Zukotynski (McMaster University) joins Dr. Aly-Khan Lalani and Dr. Christopher Wallis (he/him/his) to unpack how PSMA-targeted tracers are transforming the way we look at prostate cancer: theviewongu.ca

Not all #ProstateCancer is equal, and in Episode 20, Dr. Katherine Zukotynski of McMaster University, Dr. @LalaniMD, and Dr. Christopher Wallis (he/him/his) break down how the total burden of disease affects treatment decisions, and why it matters for every patient. Learn more: theviewongu.ca.

🚨OUT NOW: Episode 21 - featuring #ProstateCancer imaging expert, Dr. Frédéric Pouliot from Centre de recherche du CHU de Qc-Université Laval! In today’s episode, Dr. Pouillot, Dr. @LalaniMD and Dr. Christopher Wallis (he/him/his) dive into the evolving role of PSMA PET and so much more: theviewongu.ca

Great to record The View on GU | with Lalani & Wallis with Aly-Khan Lalani at #aua25 Stay tuned for the episode coming out soon!

Go #BehindTheScenes with Dr. @LalaniMD and Dr. Christopher Wallis (he/him/his) as they film live from Las Vegas at Amer. Urol. Assn.’s #AUA25! In Episode 22, dropping tomorrow, they dive into exciting #BladderCancer research and clinical trial results. theviewongu.ca

Our kidney cancer research team Dana-Farber Lank Center for Genitourinary Oncology meeting for the 1st time #legend Robert Motzer MD at #ASCO25 after the oral session ! ASCO Memorial Sloan Kettering Cancer Center

In papillary kidney cancer, particularly hereditary leiomyomatosis–associated cases, bevacizumab plus erlotinib showed strong antitumor activity. The likelihood of a response was higher in hereditary cases than in sporadic ones. Full study results: nej.md/44aWRDP

Episode 26 is now live! Join Dr. @WinsonCheung as he unpacks the evolving role of #RealWorldEvidence in #Oncology with Dr. @LalaniMD and Dr. Christopher Wallis (he/him/his). From data pitfalls to practice-changing potential, this is one conversation you don’t want to miss. theviewongu.com

Huge Congratulations 🎉 to Dr. Aly-Khan Lalani (former Dana-Farber Lank Center for Genitourinary Oncology post-doc) who keeps pushing the boundaries and excelling, now Juravinski Research Institute in Canada 🇨🇦!

#KCRS25 Excellent opening session on non clear cell RCC: arguments/fallacies, rational patient selection, trial designs, regulatory guidance — coalescing around a collaborative framework, ⬇️ barriers, ⬆️ equity Toni Choueiri, MD Hans Hammers Rana McKay, MD, FASCO ari hakimi KidneyCAN

One of the reasons I love KidneyCAN's #KCRS25: Hearing luminaries in the field of #kidneycancer present their take on data hot off the press. So cool to see Toni Choueiri, MD Robert Motzer MD Naomi Haas #McDermott sharing a stage & offering perspective on the latest from ASCO, ESMO - Eur. Oncology &